Cocrystal Pharma Q1 net loss $4.0M ($0.39/shr); cash $21.8M; pipeline milestones on track

Cocrystal Pharma, Inc.

2024-Q1 EPS reported -$0.39

Net loss improved to $4.0M ($0.39/shr) from $5.2M ($0.64/shr) in Q1 2023.
R&D expenses fell to $3.0M from $3.9M, driven by clinical-stage transitions.
Cash at March 31, 2024: $21.8M, down from $26.4M; working capital $22.1M.
Topline SAD results for oral CDI-988 (pan-coronavirus/norovirus) expected Q2 2024.
Phase 2a influenza A study of CC-42344 enrollment complete; topline due H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cocrystal Pharma, Inc. reported financial results for Q1 2024.

Period: Q1 2024
Result: reported results

Exact text from the filing

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three months ended March 31, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cocrystal Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-018798

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.